Abstract: The present disclosure relates to criteria for adaptive remeshing in debonding simulations. For example, one or more embodiments described herein include a computer-implemented method comprising determining, by a processor, a released energy, a damage parameter value, or a contact status of a contact element included within a first mesh that represents a region of physical objects simulated by a cohesive zone model. The computer-implemented method can also comprise remeshing, by the processor, a finite element associated with the contact element to generate a second mesh to represent the region based on the released energy, the damage parameter value, or the contact status to obtain physical characteristics associated with a debonding of the physical objects.

Abstract: Described herein are compositions and methods for treating a disease or disorder associated with PI3K signaling. For example, such compositions can include use of modulators of glucose metabolism, use of at least one kinase in the insulin-receptor/PI3K/AKT/mTOR pathway, and/or use of diet that influences the subject's metabolic state.

Abstract: Disclosed herein are compositions and methods relating to agents that target a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen, e.g., CD33 or EMR2, and a population of hematopoietic cells that are altered in the expression of the lineage-specific cell-surface antigen, e.g., CD33 or EMR2, for immunotherapy of hematological malignancies. Also disclosed herein are methods of administering an agent targeting more than one lineage-specific cell-surface antigen, and a population of hematopoietic cells that are altered in the expression of more than one lineage-specific cell-surface antigen, for immunotherapy of hematological malignancies. Cells comprising mutations in CD33, or EMR2, or more than one lineage-specific cell-surface antigen are also provided, as are methods of producing such cells using CRISPR-based base editor systems.

Abstract: Embodiments herein disclose methods and systems for providing a digital assistant in a device, which can generate responses to commands from a user based on ambience of the user. On receiving a command from the user of the device to perform an action, content stored in the device can be extracted. The embodiments include determining degree of privacy and sensitivity of the content. The embodiments include determining ambience of the user based on ambient noise, location of the device, presence of other humans, emotional state of the user, application parameters, user activity, and so on. The embodiments include generating a response and revealing the response based on the determined ambience and the degree of privacy and sensitivity of the extracted content. The embodiments include facilitating dialog with the user for generating appropriate responses based on the ambience of the user.

Abstract: Disclosed herein are engineered heterodimer or heterotrimer proteins which use a non-naturally occurring polypeptide domain comprising 1-5 alpha helices connected by amino acid linkers and an IgG2 hinge domain either alone or in conjunction with an IgG2 Fc domain. The heterodimer and heterodimer proteins can further comprise an antigen-binding fragment that binds a lineage-specific cell-surface antigen, a polypeptide that binds to a molecule expressed on an immune cell (e.g., natural killer cell) and/or a polypeptide that binds to a molecule expressed on another type of immune cell (e.g., T cells). Also disclosed herein are nucleic acids encoding the proteins, vectors comprising the nucleic acids, compositions, and methods of treatment.

Abstract: Disclosed herein are compositions and methods relating to agents that target a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Abstract: Disclosed herein are compositions and methods relating to fusion proteins that target a lineage-specific cell-surface antigen for treating hematological malignancies.

Abstract: A deformed mesh representing an object during a deformation process is calculated. A new mesh comprising a crack to be inserted into the deformed mesh is determined. The new mesh comprising the crack is inserted into the deformed mesh to obtain a deformed mesh having the inserted new mesh during the deformation process. This may allow for the simulation of a physical process that may not otherwise be simulated.

Abstract: Embodiments herein disclose methods and systems for providing a digital assistant in a device, which can generate responses to commands from a user based on ambience of the user. On receiving a command from the user of the device to perform an action, content stored in the device can be extracted. The embodiments include determining degree of privacy and sensitivity of the content. The embodiments include determining ambience of the user based on ambient noise, location of the device, presence of other humans, emotional state of the user, application parameters, user activity, and so on. The embodiments include generating a response and revealing the response based on the determined ambience and the degree of privacy and sensitivity of the extracted content. The embodiments include facilitating dialog with the user for generating appropriate responses based on the ambience of the user.

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen, e.g., CD33, and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen, e.g., CD33 for immunotherapy of hematological malignancies. Cells comprising mutations in CD33 are also provided, as are gRNAs targeting CD33.

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Abstract: Described herein are compositions and methods for treating a disease or disorder associated with PI3K signaling. For example, such compositions can include use of modulators of glucose metabolism, use of at least one kinase in the insulin-receptor/PI3K/O AKT/mTOR pathway, and/or use of diet that influences the subjects metabolic state.

Abstract: A deformed mesh representing an object during a deformation process is calculated. A new mesh comprising a crack to be inserted into the deformed mesh is determined. The new mesh comprising the crack is inserted into the deformed mesh to obtain a deformed mesh having the inserted new mesh during the deformation process. This may allow for the simulation of a physical process that may not otherwise be simulated.

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Abstract: Disclosed herein are compositions and methods relating to agents that target a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.